168 related articles for article (PubMed ID: 7992252)
1. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.
Cancelas JA; García-Avello A; García-Frade LJ
Thromb Res; 1994 Sep; 75(5):513-20. PubMed ID: 7992252
[TBL] [Abstract][Full Text] [Related]
2. Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia.
Pósán E; Ujj G; Kiss A; Telek B; Rák K; Udvardy M
Thromb Res; 1998 Apr; 90(2):51-6. PubMed ID: 9684757
[TBL] [Abstract][Full Text] [Related]
3. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
[TBL] [Abstract][Full Text] [Related]
4. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic imbalance in essential thrombocythemia: role of platelets.
Bazzan M; Tamponi G; Gallo E; Stella S; Schinco PC; Pannocchia A; Pileri A
Haemostasis; 1993; 23(1):38-44. PubMed ID: 8477907
[TBL] [Abstract][Full Text] [Related]
6. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
7. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
8. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
9. Laboratory investigations and prediction of thrombotic risk in polycythemia vera.
Boneu B
Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):183-5. PubMed ID: 8036139
[TBL] [Abstract][Full Text] [Related]
10. Altered plasma fibrin clot properties in essential thrombocythemia.
Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
[TBL] [Abstract][Full Text] [Related]
11. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.
Rottenstreich A; Kleinstern G; Krichevsky S; Varon D; Lavie D; Kalish Y
Eur J Intern Med; 2017 Jun; 41():49-54. PubMed ID: 27919526
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.
Falanga A; Marchetti M; Barbui T; Smith CW
Semin Hematol; 2005 Oct; 42(4):239-47. PubMed ID: 16210037
[TBL] [Abstract][Full Text] [Related]
13. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.
Bellucci S; Ignatova E; Jaillet N; Boffa MC
Thromb Haemost; 1993 Nov; 70(5):736-42. PubMed ID: 8128427
[TBL] [Abstract][Full Text] [Related]
14. Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
Hernández-Boluda JC; Gómez M
Eur J Haematol; 2015 Jan; 94(1):4-11. PubMed ID: 24814134
[TBL] [Abstract][Full Text] [Related]
15. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.
Falanga A; Marchetti M; Evangelista V; Vignoli A; Licini M; Balicco M; Manarini S; Finazzi G; Cerletti C; Barbui T
Blood; 2000 Dec; 96(13):4261-6. PubMed ID: 11110700
[TBL] [Abstract][Full Text] [Related]
16. [Fibrinolysis studied by an in vitro clot lysis test in polycythemia vera].
Pósán E; Ujj G; Kiss A; Telek B; Rák K; Udvardy M
Orv Hetil; 1996 Jan; 137(2):71-4. PubMed ID: 8721871
[TBL] [Abstract][Full Text] [Related]
17. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.
Ruggeri M; Tosetto A; Frezzato M; Rodeghiero F
Ann Intern Med; 2003 Sep; 139(6):470-5. PubMed ID: 13679323
[TBL] [Abstract][Full Text] [Related]
18. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men.
De Pergola G; De Mitrio V; Sciaraffia M; Pannacciulli N; Minenna A; Giorgino F; Petronelli M; Laudadio E; Giorgino R
Metabolism; 1997 Nov; 46(11):1287-93. PubMed ID: 9361687
[TBL] [Abstract][Full Text] [Related]
19. Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera.
Karakantza M; Giannakoulas NC; Zikos P; Sakellaropoulos G; Kouraklis A; Aktypi A; Metallinos IC; Theodori E; Zoumbos NC; Maniatis A
Int J Hematol; 2004 Apr; 79(3):253-9. PubMed ID: 15168594
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.
Dan K; Yamada T; Kimura Y; Usui N; Okamoto S; Sugihara T; Takai K; Masuda M; Mori M;
Int J Hematol; 2006 Jun; 83(5):443-9. PubMed ID: 16787877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
